Trial Profile
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy of MEDI-528, a Humanized Anti-Interleukin-9 Monoclonal Antibody, on Late Asthmatic Response Induced By Allergen Inhalation In Adults With Atopic Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Enokizumab (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- 19 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
- 17 Jul 2007 Status changed from recruiting to completed.
- 08 Nov 2006 New trial record.